ArticleCancer biology & therapy2025
MiR-135a-3p inhibits the progression of prostate cancer by targeting TLR4.
Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the expression of miR-135a-3p in prostate cancer，analyze its effects on tumor development and the involved mechanisms. A total of 125 specimens of cancer tissues and corresponding adjacent normal tissues from prostate cancer patients were collected. Real - Time quantitative PCR was employed to quantify the expression levels of miR-135a-3p in prostate cancer tissues and cell lines. Kaplan-Meier survival curve analysis and Cox regression were performed to evaluate the prognostic significance of miR-135a-3p in prostate cancer. The CCK-8 assay was used to detect cell proliferation. A dual-luciferase reporter assay was employed to validate the targeting interaction between miR-135a-3p and Toll-like receptor 4 (TLR4). miR-135a-3p is lowly expressed in prostate cancer tissues and cells, and its low expression is associated with poor prognosis of patients. The low expression state of miR-135a-3p showed a significant correlation with TNM stage, clinical stage, Gleason score, and lymph node metastasis. In addition, miR-135a-3p inhibits the proliferation of prostate cancer cells and cancer progression by negatively regulating the expression of TLR4. miR-135a-3p is downregulated in prostate cancer and is associated with poor prognosis of patients. It exerts an inhibitory effect on the progression of prostate cancer by targeting TLR4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.